Cadre (CDRE) Competitors $33.45 -1.48 (-4.23%) Closing price 05/21/2025 03:59 PM EasternExtended Trading$33.44 -0.02 (-0.05%) As of 05/21/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDRE vs. GKOS, NARI, INSP, IRTC, BLCO, TMDX, SLNO, NVST, PRCT, and LIVNShould you be buying Cadre stock or one of its competitors? The main competitors of Cadre include Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), PROCEPT BioRobotics (PRCT), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. Cadre vs. Glaukos Inari Medical Inspire Medical Systems iRhythm Technologies Bausch + Lomb TransMedics Group Soleno Therapeutics Envista PROCEPT BioRobotics LivaNova Cadre (NYSE:CDRE) and Glaukos (NYSE:GKOS) are both industrials companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk. Do analysts rate CDRE or GKOS? Cadre presently has a consensus price target of $37.00, indicating a potential upside of 10.60%. Glaukos has a consensus price target of $134.67, indicating a potential upside of 41.78%. Given Glaukos' higher probable upside, analysts clearly believe Glaukos is more favorable than Cadre.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadre 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Glaukos 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor CDRE or GKOS? In the previous week, Glaukos had 4 more articles in the media than Cadre. MarketBeat recorded 11 mentions for Glaukos and 7 mentions for Cadre. Glaukos' average media sentiment score of 1.43 beat Cadre's score of 0.64 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadre 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, CDRE or GKOS? Cadre has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadre$559.81M2.43$38.64M$0.9535.21Glaukos$404.52M13.42-$134.66M-$2.37-40.08 Does the MarketBeat Community believe in CDRE or GKOS? Glaukos received 441 more outperform votes than Cadre when rated by MarketBeat users. Likewise, 65.19% of users gave Glaukos an outperform vote while only 55.17% of users gave Cadre an outperform vote. CompanyUnderperformOutperformCadreOutperform Votes1655.17% Underperform Votes1344.83% GlaukosOutperform Votes45765.19% Underperform Votes24434.81% Which has more risk and volatility, CDRE or GKOS? Cadre has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Is CDRE or GKOS more profitable? Cadre has a net margin of 6.34% compared to Glaukos' net margin of -39.04%. Cadre's return on equity of 12.88% beat Glaukos' return on equity.Company Net Margins Return on Equity Return on Assets Cadre6.34% 12.88% 6.06% Glaukos -39.04%-16.53%-10.61% Do institutionals & insiders believe in CDRE or GKOS? 44.0% of Cadre shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 37.0% of Cadre shares are owned by company insiders. Comparatively, 5.8% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryCadre beats Glaukos on 10 of the 18 factors compared between the two stocks. Get Cadre News Delivered to You Automatically Sign up to receive the latest news and ratings for CDRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDRE vs. The Competition Export to ExcelMetricCadreSurgical appliances & supplies IndustryIndustrials SectorNYSE ExchangeMarket Cap$1.36B$9.51B$7.64B$19.41BDividend Yield1.08%1.61%4.58%3.83%P/E Ratio40.3020.8723.1434.23Price / Sales2.4363.8890.4634.85Price / Cash22.8919.6726.9417.51Price / Book6.375.053.984.69Net Income$38.64M$284.66M$807.24M$1.02B7 Day Performance-5.10%-0.47%0.71%-1.74%1 Month Performance13.65%2.15%11.03%7.46%1 Year Performance4.87%-21.59%19.30%3.96% Cadre Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDRECadre3.4742 of 5 stars$33.45-4.2%$37.00+10.6%+5.6%$1.36B$559.81M40.302,240Gap UpGKOSGlaukos4.6175 of 5 stars$94.57+5.1%$134.67+42.4%-12.5%$5.40B$404.52M-32.95780Positive NewsNARIInari Medical0.5692 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800INSPInspire Medical Systems4.672 of 5 stars$156.54+3.5%$211.91+35.4%-4.0%$4.62B$840.11M90.49760Positive NewsGap UpIRTCiRhythm Technologies1.2741 of 5 stars$137.80+0.1%$128.55-6.7%+52.9%$4.40B$618.59M-37.861,790Positive NewsBLCOBausch + Lomb4.1389 of 5 stars$11.91+5.6%$15.50+30.2%-22.8%$4.21B$4.83B-13.0812,500Gap UpTMDXTransMedics Group1.3185 of 5 stars$118.73+6.5%$126.70+6.7%-12.4%$4.02B$488.23M126.31210Positive NewsSLNOSoleno Therapeutics4.8514 of 5 stars$76.70-0.1%$106.78+39.2%+65.6%$3.87BN/A-23.1030News CoveragePositive NewsNVSTEnvista4.1759 of 5 stars$18.56+5.5%$20.08+8.2%-9.2%$3.15B$2.50B-2.8612,700Positive NewsGap UpPRCTPROCEPT BioRobotics2.9246 of 5 stars$54.44+2.5%$90.00+65.3%-17.6%$3.01B$249.12M-27.92430Positive NewsGap UpLIVNLivaNova3.7979 of 5 stars$45.23+2.7%$59.17+30.8%-27.9%$2.47B$1.28B107.692,900Positive NewsAnalyst UpgradeHigh Trading Volume Related Companies and Tools Related Companies GKOS Alternatives NARI Alternatives INSP Alternatives IRTC Alternatives BLCO Alternatives TMDX Alternatives SLNO Alternatives NVST Alternatives PRCT Alternatives LIVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CDRE) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadre Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadre With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDRE Stock Free CDRE Stock Alerts